Minimal residual disease Pipeline Summary

DelveInsight’s, “Minimal residual disease - Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Minimal residual disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Minimal residual disease: Understanding

Minimal residual disease: Overview

Minimal residual disease (MRD) describes the presence of a very small number of cancer cells that remain in the body after treatment, despite the absence of detectable disease by conventional diagnostic methods. These residual malignant cells can survive initial therapy due to incomplete treatment response or acquired resistance and may eventually proliferate, leading to disease recurrence. Monitoring MRD provides valuable insight into treatment efficacy and enables clinicians to identify patients at increased risk of relapse, allowing for timely therapeutic intervention. Because the residual tumor burden is extremely low, MRD itself is generally asymptomatic; however, progression to overt relapse may result in symptoms specific to the underlying malignancy, such as fatigue, cytopenias, or organ dysfunction.

The pathophysiology of MRD is driven by the survival of therapy-resistant cancer cells that evade eradication through mechanisms including genetic alterations, dysregulated signaling pathways, immune escape, and adaptation to protective microenvironments such as the bone marrow or central nervous system. These residual cells may remain dormant for prolonged periods or proliferate slowly while acquiring additional molecular changes that enhance their survival and resistance. Over time, clonal evolution can facilitate disease progression and clinical relapse. Consequently, MRD is considered an important biomarker of residual disease burden, treatment resistance, and the likelihood of recurrence.

Diagnosis of MRD depends on highly sensitive assays capable of identifying residual malignant cells below the detection threshold of standard microscopy. Common techniques include multiparameter flow cytometry to detect aberrant immunophenotypes, polymerase chain reaction (PCR)-based assays such as quantitative real-time PCR (RQ-PCR) and reverse transcription PCR (RT-PCR) for disease-specific genetic targets, and next-generation sequencing (NGS) to identify low-frequency tumor-associated mutations with exceptional sensitivity. MRD assessment is typically performed using bone marrow aspirates or peripheral blood samples, depending on the disease type and clinical setting. These methods are widely used to evaluate treatment response, stratify relapse risk, and support personalized treatment decisions.

Current therapeutic strategies for patients with MRD include intensified chemotherapy, proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, chimeric antigen receptor (CAR) T-cell therapies, and bispecific antibodies, depending on the underlying hematologic malignancy. MRD status is increasingly incorporated into clinical decision-making to optimize treatment duration, determine the need for consolidation or maintenance therapy, and identify candidates for novel therapeutic approaches.

"Minimal residual disease- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Minimal residual disease pipeline landscape is provided which includes the disease overview and Minimal residual disease treatment guidelines. The assessment part of the report embraces, in depth Minimal residual disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Minimal residual disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Minimal residual disease R&D. The therapies under development are focused on novel approaches to treat/improve Minimal residual disease.

Minimal residual disease Emerging Drugs Chapters

This segment of the Minimal residual disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Minimal residual disease Emerging Drugs

PRGN-3006: Precigen Inc

PRGN-3006 is an investigational autologous CD33-directed UltraCAR-T cell therapy being developed for patients with minimal residual disease (MRD)-positive acute myeloid leukemia (AML), relapsed/refractory CD33-positive AML, and higher-risk myelodysplastic syndromes (MDS). It is engineered using a non-viral Sleeping Beauty gene delivery system to express a CD33-targeting CAR, membrane-bound IL-15 to enhance T-cell persistence, and a safety switch for controlled elimination of the infused cells if needed. PRGN-3006 is being evaluated in a Phase I/Ib dose-escalation and expansion study following intravenous administration, with or without lymphodepletion, to assess its safety, tolerability, and preliminary anti-leukemic activity in MRD-positive AML and related hematologic malignancies.

Further product details are provided in the report……..

Minimal residual disease: Therapeutic Assessment

This segment of the report provides insights about the different Minimal residual disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Minimal residual disease
• There are approx. 8+ key companies which are developing the therapies for Minimal residual disease. The companies which have their Minimal residual disease drug candidates in the early stage, i.e. Phase I include, Precigen Inc.

• Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Minimal residual disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Minimal residual disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Minimal residual disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Minimal residual disease drugs.

Minimal residual disease Report Insights

• Minimal residual disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Minimal residual disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Minimal residual disease drugs?
• How many Minimal residual disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Minimal residual disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Minimal residual disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Minimal residual disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Precigen Inc
• Allogene Therapeutics
• Novartis

Key Products

• PRGN-3006
• Cemacabtagene ansegedleucel
• Rapcabtagene autoleucel